Whitfieldlevin9357

PURPOSE The aim of this study was to determine the frequency and nature of pediatric blunt chest-abdominal injuries (BCAIs) and to summarize the management of BCAIs, ranging from non-operative management (NOM) with or without angioembolization (AE) to surgical treatment. METHODS This retrospective study included patients hospitalized for BCAIs in our hospital from January 1996 to December 2017. The age, injury pattern, organs of injury, outcome, and treatment were summarized. RESULTS One hundred and thirty-two cases (98 males, 34 females, mean age 7.68 years; range 1-15 years) were summarized. Sixty patients were involved in motor-vehicle traffic injuries; 16 single bicycle injuries; 33, falls; 11, sports; 6, assault; 3, abuse; and 4, others. There were no injured organs in 31 cases, while there were 130 injured organs in 101 cases, including the liver (42), spleen (35), lung (23), kidney (13), intestine (10), pancreas (5), and adrenal gland (2). Angiography (AG) was performed in 20 cases, and NOM with AE was performed in 16 patients, including 17 organs (liver injury 9, splenic injury 5, and kidney injury 4). Surgical treatment was performed in 8 cases (splenic injury in one, pancreas injury in one, and intestinal injury in six). NOM without AE was performed in the other cases. CONCLUSIONS The management of organ injury must keep into consideration the integrated bleeding management. It is recommended that children with severe organ injury were treated in dedicated trauma centers in which AE is available. This article is protected by copyright. All rights reserved.LESSONS LEARNED This study evaluating first-line crizotinib plus pembrolizumab in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) was terminated early because increased availability of second-generation ALK inhibitors resulted in difficulty identifying and accruing eligible patients. In the small number of patients enrolled, elevated transaminases were the most common treatment-related toxicity. No other relevant toxicities were observed. Although no definitive conclusions could be drawn because of the small number of patients studied, the higher frequency of severe transaminase increases noted in this sample should be of concern if ALK inhibitor and PD-L1/PD-1 inhibitor combinations are tested in future studies. BACKGROUND Previous research suggests single-agent crizotinib is efficacious for the treatment of anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC). METHODS This study evaluated the safety and preliminary antituy study termination. © AlphaMed Press; the data published online to support this summary are the property of the authors.Recent years have witnessed remarkable advances in radical reactions involving main group metal complexes. This includes the isolation and detailed characterization of main group metal radical compounds, but also the generation of highly reactive persistent or transient radical species. A rich arsenal of methods has been established that allows control over and exploitation of their unusual reactivity patterns. Thus, main group metal compounds have entered the field of selective bond formations in controlled radical reactions. Transformations that used to be the domain of late transition metal compounds have been realized, and unusual selectivities, high activities, as well as remarkable functional group tolerances have been reported. Recent findings demonstrate the potential of main group metal compounds to become standard tools of synthetic chemistry, catalysis, and materials science, when operating via radical pathways. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.INTRODUCTION Objective response rates (ORR) appear to be higher in melanoma patients who develop immune-related adverse events (irAEs), but whether there is a similar association between irAEs and survival remains unknown. MATERIALS AND METHODS Patients with advanced melanoma treated with single-agent pembrolizumab or nivolumab in the province of Alberta from June 2014 to May 2017 were identified through the provincial pharmacy database. Chart review identified and categorized all irAEs that occurred while on anti-programmed cell death protein 1 (PD-1) checkpoint inhibitors. The primary objective was to compare overall survival (OS) with patients who developed any irAEs versus those who did not. Secondary outcomes included progression-free survival (PFS) and ORR. check details RESULTS Among 186 patients, any-grade and grade ≥3 irAEs occurred in 88 (47%) and 27 (15%) patients, respectively; one patient died of pneumonitis. In a landmark analysis excluding patients who died within the first 12 weeks, the median follow-up was-programmed cell death protein 1 (PD-1)-induced grade ≥3 immune-related adverse events (irAEs) and better patient outcomes, including overall survival. These results suggest that irAEs may be a manifestation of a patient's ability to mount a systemic immune response from PD-1-directed therapies, which may be associated with therapeutic benefit. The finding of irAEs coinciding with clinical benefit from these therapies supposes that these events are, by and large, unavoidable, and the critical management of irAEs remains essential for optimizing patient outcomes. © AlphaMed Press 2020.A highly enantioselective hydrogenation of α,β-unsaturated boronate esters catalyzed by Rh-(S)-DTBM-Segphos complex has been developed. Both (Z)-α,β- and β,β-disubstituted substrates can be successfully hydrogenated to afford chiral boronates with excellent enantioselectivities, up to 98% ee. Furthermore, the obtained chiral boronate esters, as important versatile synthetic intermediates are successfully transformed to the corresponding chiral alcohols, amines and other important derivatives with maintained enantioselectivities. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.It is well-established that females live longer than males. Paradoxically, women tend to have poorer health, a condition often named sex frailty. The aim of this study was to evaluate possible frailty predictors in older mice in a sex-specific manner, in order to employ these predictors to follow-up therapy efficiency. To further evaluate therapy effects, we also investigated the use of neurotrophic insulin-like growth factor 1 (IGF-1) gene therapy and its correlation with the expression of this frailty and emotional behaviour. In order to evaluate frailty, we employed two different approaches. We performed a frailty assessment through a 31-Item Clinical Frailty Index and through a Performance-Based 8-Item Frailty Index. Our results show that both indexes are in concordance to evaluate sex differences, but they do not correlate when evaluating IGF-1 therapy effects. Moreover, in order to reduce test-to-test variability for measures of dependent variables, we compared open field results across studies assessing sex and treatment by means of the z-score normalization.